How Does IQVIA Holdings Make its Money?
IQVIA Holdings is a leading global provider of clinical research services, healthcare analytics, and technology solutions for the life sciences industry. Formed from the 2016 merger of Quintiles (the world’s largest contract research organization) and IMS Health (the leading healthcare data company), IQVIA serves pharmaceutical companies, biotech firms, medical device makers, and public health agencies. The company manages clinical trials for drug development, provides real-world evidence analytics, and offers technology platforms that help life sciences companies commercialize their products. IQVIA’s proprietary datasets cover patient-level prescription data, medical claims, and electronic health records for over 1 billion patient records globally.
IQVIA Holdings (IQV) Business Model
IQVIA Holdings operates in the healthcare sector. Below is a summary of IQVIA Holdings’ revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from IQVIA Holdings’ 2024 fiscal year filings with the SEC.
IQVIA Holdings Competitors
IQVIA Holdings’s key competitors and comparable public companies in the healthcare sector include Thermo Fisher Scientific, Danaher, Eli Lilly, and AbbVie. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how IQVIA Holdings stacks up by comparing their revenue breakdown, margins, and growth metrics.
IQVIA Holdings Competitors
IQVIA Holdings’s key competitors and comparable public companies in the healthcare sector include Thermo Fisher Scientific, Danaher, Eli Lilly, and AbbVie. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how IQVIA Holdings stacks up by comparing their revenue breakdown, margins, and growth metrics.
IQVIA Holdings Competitors
IQVIA Holdings’s key competitors and comparable public companies in the healthcare sector include Thermo Fisher Scientific, Danaher, Eli Lilly, and AbbVie. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how IQVIA Holdings stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Technology & Analytics Solutions (Data, Analytics, Real-World Evidence) | $6,200 | $5,800 | +6.9% |
| Research & Development Solutions (Clinical Trials, CRO) | $8,600 | $8,200 | +4.9% |
| Contract Sales & Medical Solutions | $800 | $750 | +6.7% |
| Total Revenue | $15,300 | $14,900 | +2.7% |
Technology & Analytics Solutions (Data, Analytics, Real-World Evidence) — 41% of Revenue
Research & Development Solutions (Clinical Trials, CRO) — 56% of Revenue
Contract Sales & Medical Solutions — 5% of Revenue
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $15,300 | $14,900 |
| Cost of Revenue | $10,200 | $10,000 |
| Gross Profit | $5,100 | $4,900 |
| Operating Expenses | $2,400 | $2,300 |
| Operating Income | $2,700 | $2,600 |
| Net Income | $1,400 | $1,300 |
All values in millions USD unless otherwise stated.
Key Financial Metrics
- Gross Margin: 33.3%
- Operating Margin: 17.6%
- Revenue Growth: 2.7%
Is IQVIA Holdings Profitable?
Yes, IQVIA Holdings is profitable. The company reported net income of $1,400 on total revenue of $15,300. With an operating margin of 17.6%, IQVIA Holdings demonstrates solid profitability for the healthcare sector. The gross margin of 33.3% reflects IQVIA Holdings’ pricing power and cost structure.
What to Watch
- Clinical trial backlog growth and book-to-bill ratio for R&D Solutions
- AI and machine learning integration into clinical trial design and patient recruitment
- Technology & Analytics recurring revenue growth from SaaS platform adoption
- Decentralized clinical trial adoption accelerating post-pandemic
IQVIA Holdings (IQV) Financial Summary
IQVIA Holdings (IQV) is a healthcare company that generated $15,300 in total revenue in fiscal year 2024. Revenue grew 2.7% year-over-year. The company earned $1,400 in net income, making it profitable. For a deeper look at IQVIA Holdings’ revenue breakdown, business segments, and financial performance, review the detailed analysis above.